Business
Pharming Group announces 2026 financial guidance and highlights rare disease pipeline at Investor Day
Highlights advancing clinical-stage pipeline, including two major value-creating programs for primary immunodeficiencies (PIDs) with immune dysregulation and mtDNA-driven mitochondrial diseaseIntroduces napazimone (KL1333) as the compound name for the mtDNA-driven mitochondrial disease program2026 total revenue guidance of US$405 – US$425 million (8% to 13% growth)2026 total operating expense guidance of US$330 – US$335 millionInvestor Day will be webcast today starting at 10:00 am EST (16:00 CE
About this update from Pharming Group Nv
[{"type":"image","alt":"Pharming Group N.V.","displaySize":"","headline":null,"caption":"Pharming Group N.V.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":102,"url":"https://media.zenfs.com/en/globenewswire.com/e33000c1e8641d4ca14a349a419f6745"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/6VI_P53XoKPQr35Rp9bMIg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/e33000c1e8641d4ca14a349a419f6745","width":300,"height":102}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Highlights advancing clinical-stage pipeline, including two major value-creating programs for primary immunodeficiencies (PIDs) with immune dysregulation and mtDNA-driven mitochondrial disease","length":192,"tagName":"p"}]},{"val":[{"type":"text","content":"Introduces napazimone (KL1333) as the compound name for the mtDNA-driven mitochondrial disease program","length":102,"tagName":"p"}]},{"val":[{"type":"text","content":"2026 total revenue guidance of US$405 – US$425 million (8% to 13% growth)","length":73,"tagName":"p"}]},{"val":[{"type":"text","content":"2026 total operating expense guidance of US$330 – US$335 million","length":64,"tagName":"p"}]},{"val":[{"type":"text","content":"Investor Day will be webcast today starting at 10:00 am EST (16:00 CET)","length":71,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":502,"olType":false},{"type":"text","content":"Leiden, The Netherlands, February 3, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) today announced 2026 financial guidance and will highlight its advancing clinical-stage rare disease pipeline, including two major value-creating programs, at a virtual Investor Day taking place later today.","length":341,"tagName":"p"},{"type":"text","content":"The Investor Day will focus on the scientific rationale, clinical strategy, and long‑term opportunity underpinning Pharming’s pipeline programs in primary immunodeficiencies (PIDs) with immune dysregulation and mitochondrial DNA (mtDNA)‑driven mitochondrial disease.","length":266,"tagName":"p"},{"type":"text","content":"Fabrice Chouraqui, Chief Executive Officer of Pharming, commented:“Pharming’s vision of developing into a leading global rare disease company is grounded in the strength of our two commercial products an...